Revolutionizing Cancer Treatment: Exploring the Growing Immunotherapy Drugs Market by 2025
In 2019, Gilead Sciences, Inc. and Humanigen, Inc. (US) collaborated to jointly conduct a study of lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma
View full press release